XML 38 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues:      
Total revenues $ 207,539 $ 216,666 $ 180,955
Cost of revenues:      
Total cost of revenues 75,456 75,974 79,933
Gross profit 132,083 140,692 101,022
Operating expenses:      
Research and development 201,785 181,766 126,372
Sales and marketing 39,917 37,226 30,642
General and administrative 99,677 99,148 90,825
Total operating expenses 341,379 318,140 247,839
Loss from operations (209,296) (177,448) (146,817)
Other income (expense)      
Gain on equity investments 0 147,213 11,825
Change in fair value 5,683 53,461 (18,084)
Other income 17,902 19,693 3,953
Total other income (expense) 23,585 220,367 (2,306)
(Loss) income before income taxes (185,711) 42,919 (149,123)
Income tax expense 1,412 2,199 63
Net (loss) income $ (187,123) $ 40,720 $ (149,186)
Net (loss) income per share attributable to common and limited common stockholders, basic (in usd per share) $ (2.57) $ 0.57 $ (2.10)
Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares) 72,670,295 71,776,301 71,173,419
Net (loss) income per share of common and limited common stockholders, diluted (in usd per share) $ (2.57) $ 0.54 $ (2.10)
Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares) 72,670,295 74,986,816 71,173,419
Software products and services      
Revenues:      
Total revenues $ 180,365 $ 159,124 $ 135,578
Cost of revenues:      
Total cost of revenues 36,900 29,514 29,576
Drug discovery      
Revenues:      
Total revenues 27,174 57,542 45,377
Cost of revenues:      
Total cost of revenues $ 38,556 $ 46,460 $ 50,357